IL-SHIPPEO
2.4.2024 11:00:27 CEST | Business Wire | Press release
Shippeo has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Real-Time Transportation Visibility Platforms. The global multimodal shipment visibility platform was also recently named a Customers’ Choice by Gartner® in the October 2023 Gartner Peer Insights™ “Voice of the Customer”: Real-Time Transportation Visibility Platforms report, scoring the highest customer recommendation willingness rate of all providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402784237/en/
(Graphic: Shippeo)
“We are delighted to be recognized as a Leader in this latest Gartner research,” says Shippeo CEO & co-founder, Pierre Khoury. “We are also deeply thankful for the support of our wonderful customers and ecosystem partners, and incredibly proud of our talented teams. As the real-time transportation visibility (RTTV) market continues to mature in North America, Europe, and increasingly across APAC, companies are realizing the significant value visibility brings. From increasing customer NPS with more premium delivery experiences, to reducing operating costs, optimizing processes and cash flow, and monitoring and reducing carbon emissions, our platform is being recognized as an important enabler of next-generation supply chains.”
Strong growth and market momentum in North America, Asia Pacific and Europe
Over the past two years, the company’s customer base tripled. In 2023, the North American revenue grew 153% year over year, with 25% of all new revenue generated having come from companies in this region switching to Shippeo from another provider. Notable new North American customers include Amazon, Barilla, and Palermo Villa, Inc. (dba Palermo’s Pizza). The company also significantly grew its customer base in Asia Pacific, welcoming some of the region’s most recognizable brands, including Yamaha Motor. Notable customers joining in other parts of the world include Arlanxeo, Birra Peroni, DP World, Evonik, Fujifilm and Hartmann Group.
“Our approach to visibility with a greater focus on data quality and customer support has resonated extremely well with the RTTV market in North America,” says Lucien Besse, COO & co-founder at Shippeo. “Since 2020, our partnership with e2open has blossomed into a powerhouse collaboration. Through close cooperation and a shared commitment to excellence, we've achieved remarkable success together, in North America and abroad. This enduring partnership underscores our collective ability to innovate and thrive in today's dynamic landscape.”
Global multimodal visibility network
With established regional head offices in Chicago for the Americas, Singapore for APAC, and Paris for Europe, Shippeo’s network now tracks more than 50 million shipments a year across all modes, in more than 130 countries on six continents, with a 258,000-strong carrier network. Their ocean visibility network covers 99% of the world’s containerships thanks to integrations with major shipping lines. The company’s partner network has also enjoyed continued momentum, now comprising over 1000 system integrations with TMS, WMS, ERPs and telematics devices, representing a 30% increase since the start of 2022. Key strategic partners include e2open, SAP, Infor, Tesisquare, Alpega, Oracle, Siemens, Google, Snowflake, Microsoft, and BlueYonder.
The most recommended provider for three years running
Shippeo has had the highest recommendation rate of all providers on Gartner Peer Insights for over three years. In October 2023, the company was positioned in the Customers’ Choice Quadrant, having scored a 96% recommendation rate, the highest of all providers (based on 116 reviews as of August 2023).
Disclaimer:
GARTNER is a registered trademark and service mark and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner “Magic Quadrant for Real-Time Transportation Visibility Platforms 2024” by Carly West, Oscar Sanchez Duran, and Nathan Lease, 26 March 2024.
Gartner, “Voice of the Customer for Real-Time Transportation Visibility Platforms”, by Peer Contributors, 31 October 2023.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular Purpose.
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Arlanxeo, Barilla, Birra Peroni, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, DP World, Evonik, Fujifilm, Jaguar Land Rover, Hartmann Group, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, XPO Logistics and Yamaha Motor, trust Shippeo to track more than 50 million shipments per year across 130 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402784237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
